Market Closed - Euronext Paris 12:35:16 2024-03-28 pm EDT After market 02:57:46 pm
8.76 EUR 0.00% Intraday chart for Adocia 8.77 +0.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Adocia: announces fund-raising CF
Adocia SA announced that it expects to receive ?2 million in funding CI
Adocia Reveals Promising Preclinical Data on Adocia Islets for Cell Therapy of Diabetes CI
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Adocia SA announced that it has received ?9.999993 million in funding from Bpifrance Investissement SAS, Vester Finance SA CI
Sanofi Secures EUR10 Million Exclusivity Deal for Adocia's Diabetes Drug MT
Adocia Signs an Exclusivity Agreement with Sanofi for M1Pram CI
Adocia SA announced that it expects to receive €10 million in funding CI
Adocia Requests Trading Halt on Euronext Paris MT
Adocia SA Auditor Raises 'Going Concern' Doubt CI
Global markets live: Deliveroo, Adobe, Berkshire Hathaway, First republic Bank, Robinhood Markets... Our Logo
Adocia SA Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Adocia Jumps 11% as BioChaperone Lispro Shows Faster Absorption in Early-stage Insulin Injection Trial MT
Adocia SA Announces the Successful Phase 1 Study for Biochaperone® Lispro with Partner Tonghua Dongbao CI
Adocia SA announced that it has received €5.999997 million in funding CI
Adocia's Phase 2 Study of M1Pram Shows Better Weight Loss, Appetite Control in Diabetic Obese People; Shares Surge 13% MT
Adocia Sa Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes Using M1pram in A Post-Hoc Analysis CI
Adocia SA Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Adocia Obtains Preclinical Proof of Concept for Investigational Diabetes Therapy; Shares Up 9% MT
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell(R) Islets for the Treatment of Type 1 Diabetes CI
Adocia SA Reports Unaudited Revenue Results for the Second Quarter and First Half 2022 CI
Adocia SA Reports Unaudited Revenue Results for the First Quarter Ended March 31, 2022 CI
Adocia Treats First Patient in Clinical Trial for Insulin Combo MT
ADOCIA Announces First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao CI
Adocia's Chinese Partner Treats First Patient In Late-stage Study Of Diabetes Drug MT
Chart Adocia
More charts
Adocia is a biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins for the treatment of diabetes. At the end of 2022, the group had a portfolio of 4 products in clinical development (BioChaperone Lispro U100 and U200, BioChaperone Combo, M1Pram-ADO09 and BioChaperone Glucagon) and 3 preclinical-stage products (BioChaperone® LisPram, BioChaperone® Glargine GLP-1 and BioChaperone® Glucagon GLP-1).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.76 EUR
Average target price
9.7 EUR
Spread / Average Target
+10.73%
Consensus
  1. Stock
  2. Equities
  3. Stock Adocia - Euronext Paris
  4. News Adocia
  5. Adocia : Partner Wins Nod to Initiate Late-Stage Study of Diabetes Drug in China